Table 1.

Description of the main variables of the included studies (eight with Crohn’s disease patients only, two with ulcerative colitis patients, three with both UC and CD patients)

Study	Year	N	Definition of “loss of response”	ATI assay type	ATI measured
Crohn’s disease
Farrell et al. (13)	2003	53	Clinicians assessment	DA ELISA	Yes
Hanauer et al. (14)	2004	514	CDAI	DA ELISA	Yes
Maser et al. (21)	2006	105	HBI	DA ELISA	Yes
Candon et al. (58)	2006	28	HBI/surgery/non-healing fistula	DA ELISA	Yes
Ainsworth et al. (16)	2008	33	Clinicians assessment	Fluid-phase RIA	Yes
Yamada et al. (50)	2010	31	CDAI/CRP	N/A	No
Pariente et al. (20)	2011	56	HBI/clinicians assessment	DA ELISA	Yes
Steenholdt et al. (22)	2011	85	Clinicians assessment	Fluid-phase RIA	Yes
Ben Horin et al. (10)	2011	51	Clinicians assessment	AHLC ELISA	Yes
Kopylov et al. (52)	2011	63	Clinicians assessment	DA ELISA and AHLC ELISA	Yes
Imaeda et al. (19)	2012	58	CDAI	DA ELISA and IC based ELISA	Yes
Ulcerative colitis
Seow et al. (23)	2010	115	Mayo score	DA ELISA	Yes
Arias et al. (59)	2011	136	Clinicians assessment/CRP/albumin	DA ELISA	Yes
Pariente et al. (20)	2011	18	SCCAI/clinicians assessment	DA ELISA	Yes
Steenholdt et al. (22)	2011	21	Clinicians assessment	Fluid-phase RIA	Yes
Ben Horin et al. (10)	2011	11	Clinicians assessment	DA ELISA	Yes

AHLC, antihuman λ chain; ATI, antibodies to infliximab; CD, Crohn’s disease; CDI, Crohn’s disease index; DA ELISA, double antigen enzyme-linked immunoassay; HBI, Harvey Bradshaw index; IC, immunoaffinity chromatography; IFX, infliximab; LOR, loss of response; RIA, radioimmunoassay; SCCAI, Simple Clinical Colitis Activity Index; UC, ulcerative colitis.